History

We can trace our site's history back to the 1980s when we were known as Steripak and there were just ten employees and one production machine in Runcorn.

Steripak was started in 1980 by John & Ernest Prebble, with a 49% share, and Schering AG, with a 51% share, and the objective was to become the major European Pharmaceutical contract manufacturer for sterile liquids using the process of Blow Fill Seal (BFS). 

In 1985 Schering AG acquired the whole company and used the platform to launch its UK business.

In 1987 Waverley Pharmaceuticals acquired the whole share capital of Steripak from Schering AG, a company with staff experienced in the manufacturing of BFS products. The first batch of products was produced in October 1987. At that point, there were 34 people employed. Within two years, this increased to over 200 employees.

In 1992, Steripak was bought by the IVAX Corporation of Miami and became part of the Norton Healthcare Group of Companies. Norton Healthcare specialised in the manufacture of generic pharmaceutical products.

In October 2001 the Norton Healthcare Group changed its name and became IVAX Pharmaceuticals UK Ltd.

In January 2006, the IVAX corporation was acquired by Teva Pharmaceutical industries (headquartered in Israel).

Teva was founded in 1901 and by the 1990s its worldwide presence was established. In the 2000s Teva became one of the top 20 global pharmaceutical companies and by 2006 became the world's largest generic pharmaceutical company. Currently, there are 50,000 Teva employees working to improve health and enable better days.

We moved into our current Runcorn site in 2006 and we created a long-term sterile strategy to help us meet the needs of our patients in the future.

Our talent for innovation reached an exciting milestone in 2009 when we were proud to open our new production line dedicated to making Prefilled Syringe (PFS) medicines such as Teva’s innovative medicine Copaxone® (glatiramer acetate). Copaxone® is used to treat multiple sclerosis (MS) a condition affecting the central nervous system, that means it affects your nerves and it’s caused when your immune system isn’t working properly.

Our colleagues are our greatest asset and key to our success, so in 2010 (the year we began to manufacture budesonide) we created an apprenticeship program to nurture and grow new talent. Our graduate internship program followed in 2012 as we continued to grow and improve our facilities and outputs.

Teva - A global perspective

We're Teva, a global pharmaceutical company, committed to increasing access to high-quality healthcare to patients around the world.

We estimate that Teva provides medicines to 200 million patients around the world every day. 

We develop, produce and market affordable generic medicines, as well as innovative and specialty pharmaceuticals and over-the-counter consumer healthcare products, along with supplying active pharmaceutical ingredients to nearly 1,000 customers in over 100 countries. 

We work tirelessly to transform science, research and patient insights into effective treatments for disorders of the central nervous system, pain and respiratory conditions.

Every branch of our development process has the goal of improving patient outcomes at its heart. This is our promise.

At the heart of all we do is our relationship with our patients and partners - whether through a prescription medicine, over the counter treatments, or as a result of one of the many social outreach initiatives we run every year to give back to our local communities.

This is why we wake up every morning, proud to know that we enable people to live better days.